Compare Enbridge Inc (ENB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Recursion Pharmaceuticals Inc — how do they compare? Enbridge Inc trades at $46.4 (market cap $103.38B), while Recursion Pharmaceuticals Inc trades at $4.06 (market cap $2.14B). The key difference: Enbridge Inc is far larger — about 48.3× Recursion Pharmaceuticals Inc's market cap, and Enbridge Inc pays a 6.02% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| ENB | RXRX | |
|---|---|---|
Market Cap | $103.38B | $2.14B |
Volume | 3,684,305 | 30,789,535 |
Sector | Energy | Health |
52-Week High | $58.04 | $6.79 |
52-Week Low | $45.23 | $2.84 |
Typical Hold Time | 91 Days | 22 Days |
Enterprise Value | $185.39B | $1.66B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $45.89, down 1.4% on the day, with a bearish technical signal but strong recent earnings beats. The company posted $65.19B in 2025 revenue, with net income of $7.49B and a 7.34% margin. Analysts maintain a consensus buy rating with a $61.63 price target, highlighting a 6% dividend yield and robust cash flow from operations of $12.27B.
Outlook is positive due to consistent EBITDA growth, a $41B project backlog, and defensive midstream assets, though risks include high debt levels and sensitivity to interest rates. The stock offers value with a P/E of 25.54 and P/S of 1.73, supported by institutional interest and dividend stability.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
